|
Synonyms: AZD8895 | COV2-2196 | Evusheld® (tixagevimab + cilgavimab)
tixagevimab is an approved drug (EMA (2022))
Compound class:
Antibody
Comment: Tixagevimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [2]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. Tixagevimab is designed to be a long-acting agent, and in combination with cilgavimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised [1]. AstraZeneca have reported that Evusheld® retains neutralising activity against the omicron (B.1.1.529) SARS-CoV-2 variant.
|
| Bioactivity Comments |
| Binds to the trimeric S2Pecto synthetic spike protein mimic with an EC50 of 10.2 ng/ml [2]. |
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
